

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
9 August 2001 (09.08.2001)

PCT

(10) International Publication Number
WO 01/57183 A2

- (51) International Patent Classification⁷: C12N XU, Ming-Qun (CN/US); 40 Crescent Road, Hamilton, MA 01982 (US).
- (21) International Application Number: PCT/US01/03147
- (22) International Filing Date: 31 January 2001 (31.01.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/180,319 4 February 2000 (04.02.2000) US
- (71) Applicant (for all designated States except US): NEW ENGLAND BIOLABS, INC. [US/US]; 32 Tozer Road, Beverly, MA 01915 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): EVANS, Thomas, C. [US/US]; 68 Albion Street, Somerville, MA 02143 (US).
- (74) Agent: WILLIAMS, Gregory, D.; General Counsel, New England Biolabs, Inc., 32 Tozer Road, Beverly, MA 01915 (US).
- (81) Designated States (national): JP, US.
- (84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).
- Published: — without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD FOR PRODUCING CIRCULAR OR MULTIMERIC PROTEIN SPECIES *IN VIVO* OR *IN VITRO* AND RELATED METHODS

(57) Abstract: A method is disclosed for the *in vitro* or *in vivo* cyclization of protein or peptide sequences. Also disclosed is a method of fusing polypeptide sequences while bound to a solid support. These protein manipulation techniques relied on the *trans*-splicing activity of a split intein, such as the naturally occurring split intein from the *dnaE* gene of *Synechocystis* sp. PCC6803 (*Ssp* DnaE intein). The cyclization procedures required the fusion of C- and N-terminal intein splicing domains to the N- and C-termini, respectively, of a target protein (Intein_C-target protein-Intein_N). Cyclization *in vivo* occurred post-translationally when the two complementary intein splicing domains ligated the N- and C-terminus of the target protein. *In vitro* cyclization also utilized and Intein_C-target protein-Intein_N precursor protein, in which the intein domains were fused to a chitin binding domain (CBD). Protein expression was conducted under conditions that favored the accumulation of precursor protein, which was immobilized on a chitin resin. The circular protein species were eluted from the chitin resin following incubation under conditions that favored protein splicing. *Trans*-splicing was used to ligate polypeptides on a solid support by generating a protein composed of a CBD fused to a C-terminal intein splicing domain and target protein (1). This was incubated with a protein composed of target protein (2) fused to an N-terminal intein splicing domain and a CBD. The precursor proteins were immobilized on a chitin resin where *trans*-splicing resulted in the ligation of target protein (1) to target protein (2). These techniques greatly expand the procedures available for protein engineering and modification.

WO 01/57183 A2